InfuSystem Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by InfuSystem Holdings, Inc. on December 9, 2010, reporting an event that occurred on December 3, 2010. The filing addresses Item 5.02 regarding the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate governance and compensation event rather than periodic financial performance.
Material Changes
The Board of Directors approved the immediate vesting of restricted stock units (RSUs) previously granted to the Chairman, CEO, and Board members. These RSUs were originally scheduled to vest in equal installments over a three-year period. The immediate vesting represents a material change to the compensation timeline for the following individuals:
- Sean McDevitt (Chairman and CEO): 450,000 shares
- Pat LaVecchia: 250,000 shares
- John Voris: 100,000 shares
- Wayne P. Yetter: 100,000 shares
- David C. Dreyer: 75,000 shares
- James L. Freddo: 75,000 shares
- Jean-Pierre Millon: 75,000 shares
- Timothy L. Kopra: 25,000 shares
Mr. Kopra, elected to the Board on April 8, 2010, had previously received 25,000 shares of common stock and 25,000 RSUs scheduled to vest on the first anniversary of the grant date.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future operations, risks, contingencies, or unusual items beyond the specific compensation adjustment described above.
Key Facts for Investor Verification
- Verify the total number of shares issued upon immediate vesting (1,150,000 total RSUs).
- Confirm the original grant dates (April 6, 2010, for most directors; May 4, 2010, for Mr. Kopra) and the original three-year vesting schedule.
- Review the prior Form 8-K filed on April 9, 2010, for details on the initial grant terms.
- Assess the potential dilution impact of the immediate issuance of these shares on existing shareholders.